The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
Official Title: A Dose-Ranging Study of IPH2201 in Patients With Gynecologic Malignancies
Study ID: NCT02459301
Brief Summary: The purpose of this study is to test the safety of a new drug, IPH2201, to see what effects it has on this type of cancer.
Detailed Description: This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy may cause this cancer to shrink for a time, better options are needed. In laboratory tests and animals, IPH2201 has been shown to have effects which result in shrinkage of tumours. IPH2201 has been studied in people with rheumatoid arthritis but it has not yet been studied in people with cancer and the investigators do not know if it can offer better results than standard treatment. The standard or usual treatment for this disease could include surgery, chemotherapy or radiation.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Cross Cancer Institute, Edmonton, Alberta, Canada
BCCA - Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
London Regional Cancer Program, London, Ontario, Canada
University Health Network, Toronto, Ontario, Canada
CHUM - Hopital Notre-Dame, Montreal, Quebec, Canada
Name: Hal Hirte
Affiliation: Juravinski Cancer Centre at Hamilton Health Sciences, ON Canada
Role: STUDY_CHAIR
Name: Anna Tinker
Affiliation: BCCA - Vancouver Cancer Centre, BC Canada
Role: STUDY_CHAIR